AR and prostate neoplasm: Thus, a molecular model of ligand-mediated AR activation, which is based upon direct interactions between AR and the AR-interactome as well as indirect interactions between proteins that bind to the AR-interactome in a spatial and temporal context, has yet to be validated in prostate tumor cells.